As2O3, an ancient Chinese medicine, is a clinical drug for the treatment of acute promyelocytic leukemia by inducing degradation of oncogenic PML-RARα fusion proteins that result from t(15;17) translocation 52. Here, PML is linked to acute promyelocytic leukemia.